Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Why Stoke Therapeutics Stock Is Back In Focus After A Key Trial Milestone
Stoke Therapeutics (STOK) is drawing fresh attention after its Phase III EMPEROR trial for Dravet syndrome exceeded its 150 patient enrollment target, reaching 162 participants with no discontinuations reported.
See our latest analysis for Stoke Therapeutics.
At a share price of $32.14, Stoke Therapeutics has seen a 10.64% 1 month share price return and a 73.82% 1 year total shareholder return. These figures suggest building momentum as investors weigh the EMPEROR trial progress and upcoming conference appearance.
If you are looking to see how other drug developers using advanced data and RNA approaches are being priced, this is a good moment to review 42 healthcare AI stocks
The recent move in Stoke Therapeutics reflects rising expectations around EMPEROR and future FDA filing plans. The key question now is whether most of the upside is already priced in, or if valuation still leaves meaningful room ahead.
Most Popular Narrative: 28.7% Undervalued
The most followed narrative for Stoke Therapeutics pegs fair value at $45.10, compared with the last close at $32.14, which implies room between price and modelled expectations.
The analysts have a consensus price target of $45.1 for Stoke Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $35.0.
Want to see what is driving that gap between today’s price and the narrative fair value for Stoke Therapeutics? The story leans heavily on rapid revenue expansion, a sharp turn in margins, and a premium earnings multiple. Curious how those moving parts are stitched together into a single valuation view?
Result: Fair Value of $45.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Stoke Therapeutics investors still need to watch for two key swing factors: potential EMPEROR trial underperformance and tougher pricing or reimbursement decisions for zorevunersen.
Find out about the key risks to this Stoke Therapeutics narrative.
Next Steps
Given the mix of optimism and caution around Stoke Therapeutics right now, this is a good time to move quickly and check the key data for yourself. To see both the potential upside and the areas investors are worried about in one place, review the 2 key rewards and 2 important warning signs.
Looking For More Investment Ideas Beyond Stoke Therapeutics?
If you are serious about finding the next opportunity, do not stop your research with Stoke Therapeutics. The Simply Wall Street Screener surfaces ideas you may otherwise miss.
- Target future growth potential by scanning 50 high quality undervalued stocks, which combine lower market expectations with solid fundamentals and room for sentiment to shift.
- Strengthen portfolio resilience by reviewing 79 resilient stocks with low risk scores, which score well on balance sheet quality and business stability.
- Spot early opportunities by checking the screener containing 20 high quality undiscovered gems, which have strong underlying metrics yet limited current attention from the broader market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com